Neurotoxin Exposure Treatment Parkinson's Depression Research Award | Apply Online

Frequently Asked Questions (FAQs)

What is the NETPR Depression Research Award?

The Neurotoxin Exposure Treatment Parkinson's (NETPR) Depression Research Award is a FY2015 U.S. Department of Defense (DoD) grant opportunity administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA), with the Congressionally Directed Medical Research Programs (CDMRP) serving as the executing agent. This specific award mechanism focuses on depression in relation to Parkinson's disease (PD).

Which federal program and agencies are associated with this funding opportunity?

This opportunity sits within the NETPR program, established in 1997 to support high-merit Parkinson's disease research. The grant opportunity is administered by USAMRAA and executed through CDMRP.

What is the broader mission of NETPR?

NETPR funds research aimed at understanding causes of Parkinson's disease, preventing or treating the loss of dopaminergic neurons in the substantia nigra, and improving outcomes and quality of life for people living with PD. The program also emphasizes identifying surrogate markers of PD, linking clinical features to clusters of markers, and developing interventions that target biomolecular pathways connecting markers to symptoms in order to prevent, stop, or slow disease progression.

What is the main focus of this specific award mechanism?

This FY15 award mechanism narrows the NETPR mission to depression as it relates to Parkinson's disease, including depression as a non-motor complication of PD and as an epidemiologically recognized risk factor that may occur earlier in the pathway toward developing PD.

Why is depression being targeted in Parkinson's disease research under this award?

The opportunity is built around the idea that depression is both a common non-motor complication that can worsen as PD progresses and a recognized risk factor that may be involved earlier in the initiation pathway for PD. The intent is to clarify intersections between depression-related biology and PD biology and translate that knowledge into improved depression treatments for people with PD or those at elevated risk.

What is the overall goal of the NETPR Depression Research Award?

The goal is to advance research that explains how depression-related biological mechanisms intersect with Parkinson's disease biology, and to use that understanding to improve or develop treatments for depression specifically in people who already have PD or who may be at heightened risk for developing it.

What priority research areas are highlighted in the announcement?

The funding announcement highlights several priorities: (1) mapping metabolic pathways to identify molecular markers or therapy targets related to serotonergic or non-serotonergic activity; (2) identifying genetic mechanisms that contribute to depression and/or overlap between depression genetics and known PD risk factors; and (3) developing blood-based surrogate markers relevant to identifying, diagnosing, predicting susceptibility to, tracking maintenance of, or monitoring progression of depression in the context of neurodegeneration.

Does the award only support serotonergic (serotonin-linked) depression mechanisms?

No. The priorities explicitly include both serotonergic and non-serotonergic activity, reflecting interest in classic serotonin-linked mechanisms as well as alternative neurochemical pathways.

What kinds of genetic studies are of interest for this award?

The announcement emphasizes identifying genetic mechanisms contributing to depression and examining how depression genetics may overlap with other Parkinson's disease risk factors reported in the literature.

What does the opportunity mean by "blood-based surrogate markers"?

In this context, blood-based surrogate markers refer to measurable indicators in blood that could help with identifying, diagnosing, predicting susceptibility to, tracking maintenance of, or monitoring progression of depression in the setting of neurodegeneration and Parkinson's disease.

Are applicants limited to the listed priority research areas?

No. While the listed areas are primary targets, the program is open to innovative proposals outside those categories as long as the work is clearly connected to depression as either a non-motor manifestation of PD or a risk factor for PD initiation or progression, and the applicant provides a strong rationale showing alignment with the NETPR mission.

What types of studies or approaches are expected to be supported?

Projects are anticipated to lean toward preclinical research conducted in human populations, animal studies, or in silico retrospective studies.

Is preliminary data required?

Yes. A key requirement is that preliminary data must be included, indicating that proposals should be grounded in demonstrated feasibility rather than purely speculative concepts.

What PD-relevant risk factors or related phenomena are mentioned as important to connect with depression biology?

The announcement indicates interest in biological phenomena connecting depression-related pathways to other PD-relevant risk factors such as disrupted sleep architecture, long-term psychological or physiological stress, dysautonomia, and traumatic brain injury.

What outcomes is the program hoping to achieve through funded projects?

Ideally, funded research will advance understanding of serotonergic and non-serotonergic molecular pathways implicated in depression and link those pathways to PD-relevant risk factors. The expectation is that these insights will inform new treatment strategies or improvements to existing depression treatments tailored to people with PD or those at elevated risk.

What is the funding opportunity number?

The opportunity number is W81XWH-15-NETPR-DRA.

What is the CFDA number associated with this opportunity?

The announcement lists CFDA 12.420.

How is this grant categorized administratively?

It is described as a discretionary grant opportunity under the category of science and technology and other research and development.

Who is eligible to apply?

Eligibility is described as unrestricted, meaning a wide range of entity types may apply, subject to any additional eligibility clarifications provided in the full announcement.

When was the opportunity posted, and what is the application deadline?

The opportunity was posted on October 22, 2015, and the listed application deadline is December 16, 2015.

How many awards does the announcement expect to make?

The announcement indicates an expectation of making one award.

Was this award mechanism offered in prior years?

No. The announcement states this award mechanism was offered for the first time in FY15.

What is the key alignment test for proposals that are outside the named priority areas?

Proposals outside the named priority areas should still be clearly connected to depression in the context of Parkinson's disease (either as a non-motor manifestation or a risk factor) and should include a strong rationale demonstrating alignment with the NETPR mission.